Trending Stock News

Intra-Cellular Therapies, Inc. (ITCI) Reaches $19.56 After 7.00% Down Move; Black Creek Investment Management Has Lifted Its Grupo Televisa Sa (TV) Stake

Grupo Televisa, S.A.B. (NYSE:TV) Logo

The stock of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is a huge mover today! The stock decreased 1.71% or $0.34 during the last trading session, reaching $19.56. About 124,642 shares traded. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has risen 27.96% since April 19, 2017 and is uptrending. It has outperformed by 16.41% the S&P500.The move comes after 8 months negative chart setup for the $1.07B company. It was reported on Apr, 19 by Barchart.com. We have $18.19 PT which if reached, will make NASDAQ:ITCI worth $74.90M less.

Black Creek Investment Management Inc increased Grupo Televisa Sa (TV) stake by 22.67% reported in 2017Q4 SEC filing. Black Creek Investment Management Inc acquired 1.19M shares as Grupo Televisa Sa (TV)’s stock declined 16.38%. The Black Creek Investment Management Inc holds 6.41M shares with $119.71M value, up from 5.23M last quarter. Grupo Televisa Sa now has $10.06B valuation. The stock decreased 2.25% or $0.41 during the last trading session, reaching $17.78. About 313,389 shares traded. Grupo Televisa, S.A.B. (NYSE:TV) has declined 39.94% since April 19, 2017 and is downtrending. It has underperformed by 51.49% the S&P500.

Since December 11, 2017, it had 0 insider purchases, and 10 selling transactions for $2.07 million activity. Hineline Lawrence J. sold 5,062 shares worth $82,725. On Monday, December 11 LERNER RICHARD A sold $105,630 worth of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) or 7,000 shares. $17,394 worth of stock was sold by Davis Robert E on Wednesday, January 3. 6,604 shares were sold by Mates Sharon, worth $115,438. 4,220 shares were sold by Halstead Michael, worth $69,179 on Wednesday, January 3. Another trade for 1,185 shares valued at $20,583 was sold by Vanover Kimberly E..

Analysts await Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) to report earnings on May, 9. They expect $-0.65 earnings per share, down 4.84% or $0.03 from last year’s $-0.62 per share. After $-0.56 actual earnings per share reported by Intra-Cellular Therapies, Inc. for the previous quarter, Wall Street now forecasts 16.07% negative EPS growth.

Investors sentiment decreased to 1.46 in Q4 2017. Its down 1.31, from 2.77 in 2017Q3. It dived, as 21 investors sold Intra-Cellular Therapies, Inc. shares while 27 reduced holdings. 21 funds opened positions while 49 raised stakes. 37.43 million shares or 5.83% less from 39.74 million shares in 2017Q3 were reported. Moreover, State Of Wisconsin Board has 0% invested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) for 24,000 shares. Blackrock stated it has 4.00M shares. Ellington Mgmt Gp Ltd Liability Corp owns 17,000 shares. State Common Retirement Fund reported 35,700 shares or 0% of all its holdings. Moreover, Rhumbline Advisers has 0% invested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) for 43,187 shares. 22,287 are owned by Wells Fargo Commerce Mn. First Mercantile Tru stated it has 15,588 shares or 0.04% of all its holdings. Samlyn stated it has 1.00M shares. Tocqueville Asset Mgmt Limited Partnership reported 0% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Price T Rowe Assoc Incorporated Md invested 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). The Missouri-based Stifel Fincl has invested 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Art Advsrs Limited Liability holds 0.05% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) or 81,010 shares. California Pub Employees Retirement, a California-based fund reported 51,400 shares. New York-based Secor Cap Advsrs Lp has invested 0.03% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Retail Bank Of Ny Mellon stated it has 0% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI).

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including ParkinsonÂ’s and AlzheimerÂ’s disease. The company has market cap of $1.07 billion. The firm is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. It currently has negative earnings. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease.

Among 13 analysts covering Intra-Cellular Therapies (NASDAQ:ITCI), 12 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Intra-Cellular Therapies had 46 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was downgraded by Leerink Swann on Tuesday, May 2 to “Market Perform”. Ladenburg upgraded Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) on Wednesday, August 30 to “Buy” rating. The rating was maintained by Guggenheim with “Buy” on Thursday, September 17. As per Friday, August 7, the company rating was upgraded by Zacks. As per Wednesday, August 9, the company rating was maintained by Cantor Fitzgerald. As per Friday, March 2, the company rating was maintained by SunTrust. The firm has “Buy” rating given on Thursday, September 7 by Cantor Fitzgerald. Cowen & Co maintained it with “Buy” rating and $27.0 target in Friday, September 8 report. Cantor Fitzgerald maintained it with “Buy” rating and $28.0 target in Wednesday, November 8 report. The stock of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has “Buy” rating given on Wednesday, August 23 by Cowen & Co.

Among 11 analysts covering Grupo Televisa SAB (NYSE:TV), 5 have Buy rating, 0 Sell and 6 Hold. Therefore 45% are positive. Grupo Televisa SAB had 25 analyst reports since September 4, 2015 according to SRatingsIntel. The firm has “Overweight” rating by JP Morgan given on Friday, December 15. The stock has “Overweight” rating by JP Morgan on Tuesday, January 12. The firm earned “Buy” rating on Tuesday, January 24 by Bank of America. On Thursday, March 22 the stock rating was upgraded by Scotia Capital to “Hold”. The company was upgraded on Friday, January 8 by Bank of America. The rating was downgraded by HSBC on Thursday, May 12 to “Reduce”. The company was downgraded on Monday, May 9 by Citigroup. The stock has “Outperform” rating by Credit Suisse on Tuesday, September 27. The company was upgraded on Monday, December 4 by Citigroup. The stock has “Hold” rating by HSBC on Thursday, May 25.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *